United Kingdom (UK)
Recombinant monoclonal antibody to CD277. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 108.5.
UniProt Accession Number of Target Protein: O00481
Alternative Name(s) of Target: BTN3A1; BTF5; BT3; BT3.1; Butyrophilin subfamily 3 member A1
Immunogen: The original antibody was generated by immunizing BALB/c mice with soluble BT3.1-Ig fusion protein.
Specificity: This antibody binds human CD277 (BTNA3A1). This protein plays an important role in T-cell activation and in the adaptive immune response. It regulates proliferation of activated T-cells and release of IFNG by activated T-cells. It is expressed on surface of T-cells, natural killer cells, dendritic cells and macrophages (at protein level). It is highly expressed in heart, pancreas and lung and moderately expressed in placenta, liver and muscle.
Application Notes: This antibody was used as an antagonist antibody to check if BTN3A can specifically enhance Vg9Vd2 TCR-mediated lysis of primary AML blasts using cytotoxic assays. This antibody was reported to significantly and drastically abrogate zoledronate (ZOL)-induced lysis (PMID: 27853633). This antibody can completely abrogate Vγ9Vδ2 T cell mediated lysis of tumors (PMID: 29296524).
Antibody first published in:
Compte et al. Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol. 2004 Aug;34(8):2089-99. PMID:15259006
Note on publication:
This paper describes the characterization of BTN3A1 molecule expressed on immune cells using antibodies.